



**To:** Transfusion Services Managers  
**From:** Hospital Relations  
**Date:** June 23, 2022  
**Re:** HLA Matched Platelets Update

## Background

Carter BloodCare has and will continue to support complex platelet transfusion needs through its robust inventory of human leukocyte antigen (HLA) typed and matched platelets. Molecular HLA typing methods are superior to previously used serological methods. Due to the advancement in HLA typing, less ambiguous typing results can now be provided. The current match grade system (A, BU, B2U, BX, C, and D matches) will no longer be in use. Effective **Monday, August 22, 2022**, the donor match grade will be defined as follows:

Donor Match Grade	Description
A	All 4 antigens in the donor are identical with all 4 antigens present in the recipient (including formerly B1U and B2U match grades)
B1X – B4X	1 to 4 antigens in the donor are cross reactive with the antigens present in the recipient and the other antigens are identical to the recipient
C1	1 antigen is mismatched with the recipient and the other antigens are cross reactive or identical to the recipient

A blank antigen in either the A or B locus will be assumed to be a homozygous pair, or a double dose of the one present antigen.

## Impact to Client

- This will replace the previous definitions of donor classifications for match grades.
- HLA matched platelets will follow the same current procedure for providing match grade results by attaching the form to the manila tie tag on the unit.
- There are no ISBT product code updates to be made with this change.
- Please review and update your policies and procedures to reflect this update in preparation of the **August 22, 2022** effective date.
- Inform laboratory medical directors and appropriate clinicians.

## Questions and Additional Information

Please contact Hospital Relations at [hospitalrelations@carterbloodcare.org](mailto:hospitalrelations@carterbloodcare.org) with any questions or concerns.